A newer GLP-1 receptor agonist, tirzepatide, demonstrates weight loss as high as 20% change in body weight compared with 3% in the placebo group in a RCT
This limits generalizability and does not mirror most of the type 1 diabetes patients seen in nephrology practice
These products have not been tested in large, randomized clinical trials, may vary in strength or purity, and may not even contain the same active ingredient as FDA-approved semaglutide, said Fatima Cody Stanford, MD, MPH, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School, both in Boston
Who Is A Good Candidate For Lipotropic Injections
Semaglutide side effects and tirzepatide side effects are most common during dose increases primarily GI symptoms like GLP-1 nausea and typically improve as your body adjusts
Yes, incorporating cranberry products may provide additional benefits in preventing UTIs